Tempus AI, Inc. (TEM) has a MoatMap StockRank of 12/100 based on Quality (35/100), Value (37/100), and Momentum (24/100) factor scores. The current signal is STRONG SELL. A healthcare data and genomics company. While it has a high-growth narrative around AI, it is currently unprofitable, has low quality metrics, and does not meet our strict Terry Smith or Buffett criteria for high ROIC and positive owner earnings.
Tempus AI, Inc. is a technology company focused on advancing precision medicine by collecting and analyzing large volumes of molecular and clinical data. It provides physicians with data-driven insights and tools to make informed treatment decisions, particularly in oncology and other complex diseases, through its AI-powered platform. Tempus holds a niche market position as a leader in real-world data and genomic sequencing for healthcare, facilitating personalized medicine and drug discovery.
| Price | $47.51 |
| Market Cap | $9.2B |
| P/E (Forward) | -339.35 |
| Price/Book | 16.91 |
| Return on Equity | -81.6% |
| Return on Invested Capital | -11.6% |
| Debt/Equity | 316.65 |
| Gross Margin | 63.4% |
| Operating Margin | -24.3% |
| Revenue Growth | 36.1% |
| Free Cash Flow | $-56M |
Tempus AI, Inc. operates in the Health Information Services industry, part of the Healthcare sector (United States).